Multi-Agent Portfolio

# MAP Post-Market Debate — 2026-10-01

## Ronda 1 y Ronda 2 — lectura ejecutiva

### Sentiment
El mercado está selectivo y cauteloso: SPY cerró en $763.99 y acumula -0.95% en cinco ruedas, sin rally amplio ni breakouts confirmados. AI/cloud sigue atrayendo capital en MSFT y AMZN, pero el tape exige monetización; GOOGL, JPM y LLY tienen calidad, aunque no apetito inmediato. IOVA, KOD y TWST tienen catalizadores pero la extensión convierte la atención en riesgo de chase.

### Quant
Tape frágil: no hay breakouts 20d confirmados; XOM es la estructura relativa más limpia, aunque con volumen seco. MSFT mantiene tendencia sana cerca de resistencia; GOOGL, AMZN, JPM, BRK-B, V y ZYME siguen en reparación o presión. La regla dura se mantuvo: extended_chase, breakdown y soporte sin reversión no se suavizan por narrativa.

### Fundamental
MSFT, GOOGL, AMZN, JPM, LLY y V muestran negocios de calidad; XOM es más cíclico y ZYME es especulativo. Los múltiplos, márgenes y crecimiento no sustituyen la confirmación del precio. Los catalizadores de X se trataron como discurso, no como dato contable; biotech mantiene riesgo binario.

## Scorecard
- **AKAM** — CS 0.391 (Quant 0.32 / Fund 0.48 / Sent 0.38) → **PASS** · **VETO Risk**: AI/cloud narrative is not confirmed by price; AKAM is below MA20 in repair, revenue growth is only 5.4%, earnings growth is negative and valuation is demanding. Block anticipatory sizing.
- **AMZN** — CS 0.544 (Quant 0.37 / Fund 0.76 / Sent 0.52) → **PASS** · **VETO Risk**: Correlated mega-cap/growth exposure is already approximately 30.5% of the book; AMZN is below MA20/MA50 in repair with fragile nearby support and no confirmed reversal. Block ADD until confirmation.
- **APLD** — CS 0.373 (Quant 0.40 / Fund 0.40 / Sent 0.29) → **PASS** · **VETO Risk**: Breakdown and financing/execution risk: -10.717% in five days, 7.532% below MA20, negative margin and high capex sensitivity. Block new exposure until repair and funding evidence.
- **BRK-B** — CS 0.539 (Quant 0.45 / Fund 0.74 / Sent 0.40) → **PASS** · **VETO Risk**: Adds would increase the existing Financial Services concentration; price is below MA20 and only 0.512% above support with no reversal confirmation. Block ADD, but no thesis-break sell is warranted.
- **GOOGL** — CS 0.520 (Quant 0.24 / Fund 0.82 / Sent 0.55) → **WATCHLIST**
- **IOVA** — CS 0.365 (Quant 0.40 / Fund 0.30 / Sent 0.40) → **PASS** · **VETO Risk**: Aggressive extended chase: +31.759% in five days, 37.203% above MA20, RSI 85.86, deep negative margin and binary biotech/commercial risk. Absolute BUY/ADD veto.
- **JPM** — CS 0.443 (Quant 0.29 / Fund 0.72 / Sent 0.30) → **PASS** · **VETO Risk**: Financial Services cluster (JPM, BRK-B, V) is approximately 19.3%; JPM is 3.927% below MA20, oversold and near support without demand confirmation. Block ADD while technical damage persists.
- **KMX** — CS 0.385 (Quant 0.40 / Fund 0.40 / Sent 0.34) → **PASS** · **VETO Risk**: Repair remains incomplete: 5.028% below MA20, near support, very thin 0.99% margin and consumer/auto cyclicality. Beat and buybacks do not confirm a reversal; block ADD.
- **KOD** — CS 0.262 (Quant 0.40 / Fund 0.12 / Sent 0.24) → **PASS** · **VETO Risk**: Extreme post-catalyst chase: +196.388% in five days, 116.777% above MA20, RSI 94.62 and price next to resistance, with no usable financial base and regulatory risk. Absolute BUY/ADD veto.
- **LLY** — CS 0.596 (Quant 0.46 / Fund 0.77 / Sent 0.57) → **PASS** · **VETO Risk**: Healthcare growth exposure is already meaningful through LLY plus speculative biotech candidates; LLY is below MA50 and lacks breakout confirmation. Avoid increasing size at elevated valuation until tape improves.
- **MSFT** — CS 0.714 (Quant 0.66 / Fund 0.80 / Sent 0.68) → **PASS** · **VETO Risk**: Concentration/crowding in correlated mega-cap growth, position remains above its 12% target, and price is 1.352% below resistance without breakout confirmation; trim-first, no BUY/ADD.
- **TWST** — CS 0.241 (Quant 0.06 / Fund 0.40 / Sent 0.31) → **PASS** · **VETO Risk**: Extended chase: RSI 81.34, 21.23% above MA20, near resistance and no confirmed breakout; negative margin and analyst-target narrative do not justify late entry.
- **V** — CS 0.486 (Quant 0.30 / Fund 0.76 / Sent 0.40) → **PASS** · **VETO Risk**: Financial Services concentration is already approximately 19.3%; V remains 2.337% below MA20, near support, with weak tape and no reversal. Block ADD and avoid automatic recompra.
- **VKTX** — CS 0.173 (Quant 0.12 / Fund 0.18 / Sent 0.25) → **PASS** · **VETO Risk**: Severe breakdown: -16.98% in five days and 7.763% below MA20, with speculative clinical thesis, no verified revenue/PE and binary risk. Absolute BUY/ADD veto until confirmed repair.
- **XOM** — CS 0.600 (Quant 0.68 / Fund 0.65 / Sent 0.40) → **WATCHLIST**
- **ZYME** — CS 0.308 (Quant 0.17 / Fund 0.40 / Sent 0.40) → **PASS** · **VETO Risk**: Speculative runner with weak/uncertain fundamentals, breakdown structure, dry volume and no confirmed demand; risk of permanent loss outweighs any support-based add. No recompra automática.

## Risk
Cash post-mercado $3,064.96 (31.9% del book), muy por encima del mínimo de $500; no hay obligación de full deploy. La concentración estimada más alta es Financial Services (~19.3%) y mega-cap/growth correlacionado (~30.5%). Veto absoluto para nuevas compras en los nombres marcados; trim-first en MSFT y ZYME. No se confirmó thesis-break que obligue a liquidar el resto.

## Decisión PM
No hubo BUY/ADD. Se ejecutó TRIM de 0.2 MSFT a $512.80 (aprox. $102.56) y 1 ZYME a $25.96 (aprox. $25.96). GOOGL y XOM quedan en WATCHLIST, no son órdenes: esperar recuperación/breakout con volumen. Se conserva liquidez de forma intencional.

# MAP Post-Market Debate — 2026-10-01

## Ronda 1 y Ronda 2 — lectura ejecutiva

### Sentiment
El mercado está selectivo y cauteloso: SPY cerró en $763.99 y acumula -0.95% en cinco ruedas, sin rally amplio ni breakouts confirmados. AI/cloud sigue atrayendo capital en MSFT y AMZN, pero el tape exige monetización; GOOGL, JPM y LLY tienen calidad, aunque no apetito inmediato. IOVA, KOD y TWST tienen catalizadores pero la extensión convierte la atención en riesgo de chase.

### Quant
Tape frágil: no hay breakouts 20d confirmados; XOM es la estructura relativa más limpia, aunque con volumen seco. MSFT mantiene tendencia sana cerca de resistencia; GOOGL, AMZN, JPM, BRK-B, V y ZYME siguen en reparación o presión. La regla dura se mantuvo: extended_chase, breakdown y soporte sin reversión no se suavizan por narrativa.

### Fundamental
MSFT, GOOGL, AMZN, JPM, LLY y V muestran negocios de calidad; XOM es más cíclico y ZYME es especulativo. Los múltiplos, márgenes y crecimiento no sustituyen la confirmación del precio. Los catalizadores de X se trataron como discurso, no como dato contable; biotech mantiene riesgo binario.

## Scorecard
- **AKAM** — CS 0.391 (Quant 0.32 / Fund 0.48 / Sent 0.38) → **PASS** · **VETO Risk**: AI/cloud narrative is not confirmed by price; AKAM is below MA20 in repair, revenue growth is only 5.4%, earnings growth is negative and valuation is demanding. Block anticipatory sizing.
- **AMZN** — CS 0.544 (Quant 0.37 / Fund 0.76 / Sent 0.52) → **PASS** · **VETO Risk**: Correlated mega-cap/growth exposure is already approximately 30.5% of the book; AMZN is below MA20/MA50 in repair with fragile nearby support and no confirmed reversal. Block ADD until confirmation.
- **APLD** — CS 0.373 (Quant 0.40 / Fund 0.40 / Sent 0.29) → **PASS** · **VETO Risk**: Breakdown and financing/execution risk: -10.717% in five days, 7.532% below MA20, negative margin and high capex sensitivity. Block new exposure until repair and funding evidence.
- **BRK-B** — CS 0.539 (Quant 0.45 / Fund 0.74 / Sent 0.40) → **PASS** · **VETO Risk**: Adds would increase the existing Financial Services concentration; price is below MA20 and only 0.512% above support with no reversal confirmation. Block ADD, but no thesis-break sell is warranted.
- **GOOGL** — CS 0.520 (Quant 0.24 / Fund 0.82 / Sent 0.55) → **WATCHLIST**
- **IOVA** — CS 0.365 (Quant 0.40 / Fund 0.30 / Sent 0.40) → **PASS** · **VETO Risk**: Aggressive extended chase: +31.759% in five days, 37.203% above MA20, RSI 85.86, deep negative margin and binary biotech/commercial risk. Absolute BUY/ADD veto.
- **JPM** — CS 0.443 (Quant 0.29 / Fund 0.72 / Sent 0.30) → **PASS** · **VETO Risk**: Financial Services cluster (JPM, BRK-B, V) is approximately 19.3%; JPM is 3.927% below MA20, oversold and near support without demand confirmation. Block ADD while technical damage persists.
- **KMX** — CS 0.385 (Quant 0.40 / Fund 0.40 / Sent 0.34) → **PASS** · **VETO Risk**: Repair remains incomplete: 5.028% below MA20, near support, very thin 0.99% margin and consumer/auto cyclicality. Beat and buybacks do not confirm a reversal; block ADD.
- **KOD** — CS 0.262 (Quant 0.40 / Fund 0.12 / Sent 0.24) → **PASS** · **VETO Risk**: Extreme post-catalyst chase: +196.388% in five days, 116.777% above MA20, RSI 94.62 and price next to resistance, with no usable financial base and regulatory risk. Absolute BUY/ADD veto.
- **LLY** — CS 0.596 (Quant 0.46 / Fund 0.77 / Sent 0.57) → **PASS** · **VETO Risk**: Healthcare growth exposure is already meaningful through LLY plus speculative biotech candidates; LLY is below MA50 and lacks breakout confirmation. Avoid increasing size at elevated valuation until tape improves.
- **MSFT** — CS 0.714 (Quant 0.66 / Fund 0.80 / Sent 0.68) → **PASS** · **VETO Risk**: Concentration/crowding in correlated mega-cap growth, position remains above its 12% target, and price is 1.352% below resistance without breakout confirmation; trim-first, no BUY/ADD.
- **TWST** — CS 0.241 (Quant 0.06 / Fund 0.40 / Sent 0.31) → **PASS** · **VETO Risk**: Extended chase: RSI 81.34, 21.23% above MA20, near resistance and no confirmed breakout; negative margin and analyst-target narrative do not justify late entry.
- **V** — CS 0.486 (Quant 0.30 / Fund 0.76 / Sent 0.40) → **PASS** · **VETO Risk**: Financial Services concentration is already approximately 19.3%; V remains 2.337% below MA20, near support, with weak tape and no reversal. Block ADD and avoid automatic recompra.
- **VKTX** — CS 0.173 (Quant 0.12 / Fund 0.18 / Sent 0.25) → **PASS** · **VETO Risk**: Severe breakdown: -16.98% in five days and 7.763% below MA20, with speculative clinical thesis, no verified revenue/PE and binary risk. Absolute BUY/ADD veto until confirmed repair.
- **XOM** — CS 0.600 (Quant 0.68 / Fund 0.65 / Sent 0.40) → **WATCHLIST**
- **ZYME** — CS 0.308 (Quant 0.17 / Fund 0.40 / Sent 0.40) → **PASS** · **VETO Risk**: Speculative runner with weak/uncertain fundamentals, breakdown structure, dry volume and no confirmed demand; risk of permanent loss outweighs any support-based add. No recompra automática.

## Risk
Cash post-mercado $3,064.96 (31.9% del book), muy por encima del mínimo de $500; no hay obligación de full deploy. La concentración estimada más alta es Financial Services (~19.3%) y mega-cap/growth correlacionado (~30.5%). Veto absoluto para nuevas compras en los nombres marcados; trim-first en MSFT y ZYME. No se confirmó thesis-break que obligue a liquidar el resto.

## Decisión PM
No hubo BUY/ADD. Se ejecutó TRIM de 0.2 MSFT a $512.80 (aprox. $102.56) y 1 ZYME a $25.96 (aprox. $25.96). GOOGL y XOM quedan en WATCHLIST, no son órdenes: esperar recuperación/breakout con volumen. Se conserva liquidez de forma intencional.

# MAP Post-Market Debate — 2026-10-01

## Ronda 1 y Ronda 2 — lectura ejecutiva

### Sentiment
El mercado está selectivo y cauteloso: SPY cerró en $763.99 y acumula -0.95% en cinco ruedas, sin rally amplio ni breakouts confirmados. AI/cloud sigue atrayendo capital en MSFT y AMZN, pero el tape exige monetización; GOOGL, JPM y LLY tienen calidad, aunque no apetito inmediato. IOVA, KOD y TWST tienen catalizadores pero la extensión convierte la atención en riesgo de chase.

### Quant
Tape frágil: no hay breakouts 20d confirmados; XOM es la estructura relativa más limpia, aunque con volumen seco. MSFT mantiene tendencia sana cerca de resistencia; GOOGL, AMZN, JPM, BRK-B, V y ZYME siguen en reparación o presión. La regla dura se mantuvo: extended_chase, breakdown y soporte sin reversión no se suavizan por narrativa.

### Fundamental
MSFT, GOOGL, AMZN, JPM, LLY y V muestran negocios de calidad; XOM es más cíclico y ZYME es especulativo. Los múltiplos, márgenes y crecimiento no sustituyen la confirmación del precio. Los catalizadores de X se trataron como discurso, no como dato contable; biotech mantiene riesgo binario.

## Scorecard
- **AKAM** — CS 0.391 (Quant 0.32 / Fund 0.48 / Sent 0.38) → **PASS** · **VETO Risk**: AI/cloud narrative is not confirmed by price; AKAM is below MA20 in repair, revenue growth is only 5.4%, earnings growth is negative and valuation is demanding. Block anticipatory sizing.
- **AMZN** — CS 0.544 (Quant 0.37 / Fund 0.76 / Sent 0.52) → **PASS** · **VETO Risk**: Correlated mega-cap/growth exposure is already approximately 30.5% of the book; AMZN is below MA20/MA50 in repair with fragile nearby support and no confirmed reversal. Block ADD until confirmation.
- **APLD** — CS 0.373 (Quant 0.40 / Fund 0.40 / Sent 0.29) → **PASS** · **VETO Risk**: Breakdown and financing/execution risk: -10.717% in five days, 7.532% below MA20, negative margin and high capex sensitivity. Block new exposure until repair and funding evidence.
- **BRK-B** — CS 0.539 (Quant 0.45 / Fund 0.74 / Sent 0.40) → **PASS** · **VETO Risk**: Adds would increase the existing Financial Services concentration; price is below MA20 and only 0.512% above support with no reversal confirmation. Block ADD, but no thesis-break sell is warranted.
- **GOOGL** — CS 0.520 (Quant 0.24 / Fund 0.82 / Sent 0.55) → **WATCHLIST**
- **IOVA** — CS 0.365 (Quant 0.40 / Fund 0.30 / Sent 0.40) → **PASS** · **VETO Risk**: Aggressive extended chase: +31.759% in five days, 37.203% above MA20, RSI 85.86, deep negative margin and binary biotech/commercial risk. Absolute BUY/ADD veto.
- **JPM** — CS 0.443 (Quant 0.29 / Fund 0.72 / Sent 0.30) → **PASS** · **VETO Risk**: Financial Services cluster (JPM, BRK-B, V) is approximately 19.3%; JPM is 3.927% below MA20, oversold and near support without demand confirmation. Block ADD while technical damage persists.
- **KMX** — CS 0.385 (Quant 0.40 / Fund 0.40 / Sent 0.34) → **PASS** · **VETO Risk**: Repair remains incomplete: 5.028% below MA20, near support, very thin 0.99% margin and consumer/auto cyclicality. Beat and buybacks do not confirm a reversal; block ADD.
- **KOD** — CS 0.262 (Quant 0.40 / Fund 0.12 / Sent 0.24) → **PASS** · **VETO Risk**: Extreme post-catalyst chase: +196.388% in five days, 116.777% above MA20, RSI 94.62 and price next to resistance, with no usable financial base and regulatory risk. Absolute BUY/ADD veto.
- **LLY** — CS 0.596 (Quant 0.46 / Fund 0.77 / Sent 0.57) → **PASS** · **VETO Risk**: Healthcare growth exposure is already meaningful through LLY plus speculative biotech candidates; LLY is below MA50 and lacks breakout confirmation. Avoid increasing size at elevated valuation until tape improves.
- **MSFT** — CS 0.714 (Quant 0.66 / Fund 0.80 / Sent 0.68) → **PASS** · **VETO Risk**: Concentration/crowding in correlated mega-cap growth, position remains above its 12% target, and price is 1.352% below resistance without breakout confirmation; trim-first, no BUY/ADD.
- **TWST** — CS 0.241 (Quant 0.06 / Fund 0.40 / Sent 0.31) → **PASS** · **VETO Risk**: Extended chase: RSI 81.34, 21.23% above MA20, near resistance and no confirmed breakout; negative margin and analyst-target narrative do not justify late entry.
- **V** — CS 0.486 (Quant 0.30 / Fund 0.76 / Sent 0.40) → **PASS** · **VETO Risk**: Financial Services concentration is already approximately 19.3%; V remains 2.337% below MA20, near support, with weak tape and no reversal. Block ADD and avoid automatic recompra.
- **VKTX** — CS 0.173 (Quant 0.12 / Fund 0.18 / Sent 0.25) → **PASS** · **VETO Risk**: Severe breakdown: -16.98% in five days and 7.763% below MA20, with speculative clinical thesis, no verified revenue/PE and binary risk. Absolute BUY/ADD veto until confirmed repair.
- **XOM** — CS 0.600 (Quant 0.68 / Fund 0.65 / Sent 0.40) → **WATCHLIST**
- **ZYME** — CS 0.308 (Quant 0.17 / Fund 0.40 / Sent 0.40) → **PASS** · **VETO Risk**: Speculative runner with weak/uncertain fundamentals, breakdown structure, dry volume and no confirmed demand; risk of permanent loss outweighs any support-based add. No recompra automática.

## Risk
Cash post-mercado $3,064.96 (31.9% del book), muy por encima del mínimo de $500; no hay obligación de full deploy. La concentración estimada más alta es Financial Services (~19.3%) y mega-cap/growth correlacionado (~30.5%). Veto absoluto para nuevas compras en los nombres marcados; trim-first en MSFT y ZYME. No se confirmó thesis-break que obligue a liquidar el resto.

## Decisión PM
No hubo BUY/ADD. Se ejecutó TRIM de 0.2 MSFT a $512.80 (aprox. $102.56) y 1 ZYME a $25.96 (aprox. $25.96). GOOGL y XOM quedan en WATCHLIST, no son órdenes: esperar recuperación/breakout con volumen. Se conserva liquidez de forma intencional.